Sign In
Buy FATE
$2.45
-0.0600 (-2.39%)
At Close: Jul 31, 2026
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 01'st May 2026
SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent st
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent
Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference
01:03am, Thursday, 16'th Apr 2026
Fate Therapeutics (NASDAQ: FATE) used a presentation at the Needham Healthcare Conference to outline its strategy for developing "off-the-shelf" CAR T-cell therapies, highlighting clinical progress in
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 02'nd Apr 2026
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent
Scalable Biotech Manufacturing Unlocks a $14B Market
09:15am, Friday, 27'th Mar 2026
/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy manufacturing market is hitting a pivotal inflection point. It's projected to
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of “Hold” from Brokerages
02:56am, Monday, 23'rd Mar 2026
Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) has earned an average rating of "Hold" from the eight ratings firms that are covering the company, Marketbeat reports. One investment analyst h
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 04'th Mar 2026
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
04:05pm, Tuesday, 03'rd Mar 2026
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
10:02am, Tuesday, 03'rd Mar 2026
/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates
02:31pm, Thursday, 26'th Feb 2026
Fate Therapeutics (FATE) came out with a quarterly loss of $0.27 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.31 per share a year ago.
The iPSC-derived NK cells clinical trial analysis report delivers important insights into ongoing research of 15+ pipeline iPSC-derived NK cells drugs, clinical strategies, upcoming therapeutics, and
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 03'rd Feb 2026
SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts
02:44am, Sunday, 01'st Feb 2026
Shares of Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) have received a consensus recommendation of "Hold" from the nine analysts that are covering the firm, Marketbeat.com reports. One ana
Cindy Tahl Sells 10,589 Shares of Fate Therapeutics (NASDAQ:FATE) Stock
04:48am, Wednesday, 14'th Jan 2026
Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) insider Cindy Tahl sold 10,589 shares of the firm's stock in a transaction dated Friday, January 9th. The shares were sold at an average price
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of “Hold” from Brokerages
02:00am, Wednesday, 07'th Jan 2026
Shares of Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) have received a consensus recommendation of "Hold" from the nine ratings firms that are currently covering the firm, Marketbeat Ratin
